| dc.contributor.author | ROWIN, J | |
| dc.contributor.author | Tuzun, Erdem | |
| dc.contributor.author | YANG, H | |
| dc.contributor.author | CHRISTADOSS, P | |
| dc.contributor.author | MERIGGIOLI, MN | |
| dc.date.accessioned | 2021-03-04T12:20:13Z | |
| dc.date.available | 2021-03-04T12:20:13Z | |
| dc.date.issued | 2005 | |
| dc.identifier.citation | Tuzun E., MERIGGIOLI M., ROWIN J., YANG H., CHRISTADOSS P., "Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment", JOURNAL OF AUTOIMMUNITY, cilt.24, sa.3, ss.261-268, 2005 | |
| dc.identifier.issn | 0896-8411 | |
| dc.identifier.other | av_76c3149d-a9a7-4934-a53c-9628c203b835 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/81548 | |
| dc.identifier.uri | https://doi.org/10.1016/j.jaut.2005.01.013 | |
| dc.description.abstract | Steroid-dependent myasthenia gravis patients improved following treatment with etanercept (recombinant human TNF receptor: Fc) in a prospective pilot trial. While the plasma anti -acetylcholine receptor antibody levels remained unaffected, etanercept treatment increased plasma levels of C3, circulating immune coniplexes, IL-10 and IFN-gamma. There was a direct correlation between plasma IL-6, TNF-alpha and IFN-gamma levels and the post-treatment clinical scores of patients. Moreover, patients with lower pretreatment plasma IL-6 and IFN-gamma levels attained better clinical improvement following etanercept treatment. (c) 2005 Elsevier Ltd. All rights reserved. | |
| dc.language.iso | eng | |
| dc.subject | Yaşam Bilimleri | |
| dc.subject | İmmünoloji | |
| dc.subject | Yaşam Bilimleri (LIFE) | |
| dc.subject | Temel Bilimler | |
| dc.title | Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment | |
| dc.type | Makale | |
| dc.relation.journal | JOURNAL OF AUTOIMMUNITY | |
| dc.contributor.department | , , | |
| dc.identifier.volume | 24 | |
| dc.identifier.issue | 3 | |
| dc.identifier.startpage | 261 | |
| dc.identifier.endpage | 268 | |
| dc.contributor.firstauthorID | 1842 | |
